TriSalus Life Sciences, Inc.: 5%+ holders

As of November 9, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of TriSalus Life Sciences, Inc. The largest reported stake is Frankenius Equity AB's, at 14%. 10 filings are on record since August 1, 2025 (Schedule 13D/A, August 4, 2025).

First Light Asset Management, LLC also filed stake reports on 12 other companies ↓

Sell to companies like TriSalus Life Sciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-07-07 · Reporting person: First Light Asset Management, LLC · Sole voting: 0 · Shared voting: 6,596,242 · Sole dispositive: 0 · Shared dispositive: 6,596,242 · SCHEDULE 13G/A, 2026-07-07
• Filed 2026-05-20 · Holder: James J. Pallotta · Percent: 5.2% · SCHEDULE 13G/A
• Filed 2026-05-15 · Holder: First Light Asset Management, LLC · Percent: 8.75% · SCHEDULE 13G
• Filed 2026-05-12 · Holder: Utmost Group PLC · Percent: 5.71% · SCHEDULE 13G
• Filed 2025-11-14 · Holder: Nantahala Capital Management, LLC · Percent: 4.09% · SCHEDULE 13G/A

TriSalus Life Sciences, Inc. has 10 Schedule 13D or 13G filings on record since 2025-08-01. 5 holders' latest filing reports 5% or more of common stock, $0.01 par value. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind TriSalus Life Sciences, Inc. and the warning signs.

See TriSalus Life Sciences, Inc.'s free Snapshot Watch TriSalus Life Sciences, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on TriSalus Life Sciences, Inc. and the records around it.

TriSalus Life Sciences, Inc. elsewhere on the record

• Leadership changes Apr 2026
• Form D filing May 2025
• Who owns it

Companies that share a holder

• First Light Asset Management, LLC also filed stake reports on 12 other companies: NeuroPace Inc (Sep 2026), Neogenomics, Inc. (Aug 2026), PALVELLA THERAPEUTICS, INC. (Aug 2026)
• Nantahala Capital Management, LLC also filed stake reports on 70 other companies: Research Alliance Corp III (Oct 2026), ADC Therapeutics SA (Aug 2026), Anteris Technologies Global Corp. (Aug 2026)

Want the whole picture on TriSalus Life Sciences, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on TriSalus Life Sciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on TriSalus Life Sciences, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies TriSalus Life Sciences, Inc. by CUSIP 89680M101 and gives its principal executive office as 6272 W. 91st Ave., Westminster, CO 80031 (SCHEDULE 13G/A, 2026-07-07).

Purpose of Transaction (Item 4)

Mats Wahlstrom

Item 4 of the Statement is hereby amended and supplemented as follows: On June 23, 2025, the Issuer filed a Form S-4 announcing the Exchange Offer (the "Offer") of Common Stock in exchange for the shares of the Issuer's Preferred Stock, which equated to an exchange ratio of 3.3 shares of Common Stock for each share of Preferred Stock exchanged pursuant to the Offer. The Offer expired at one minute after 11:59 P.M. Eastern Daylight Time on July 23, 2025 and the conversions were completed on July 31, 2025. Leonard Capital, LLC. accepted the Exchange and was issued 165,000 shares of Common Stock in exchange for their 50,000 shares of Preferred Stock.Item 4 of the SCHEDULE 13D/A filed 2025-08-01

Frankenius Equity AB

Item 4 of the Statement is hereby amended and supplemented as follows: On June 23, 2025, the Issuer filed a Form S-4 announcing the Exchange Offer (the "Offer") of Common Stock in exchange for the shares of the Issuer's Preferred Stock, which equated to an exchange ratio of 3.3 shares of Common Stock for each share of Preferred Stock exchanged pursuant to the Offer. The Offer expired at one minute after 11:59 P.M. Eastern Daylight Time on July 23, 2025 and the conversions were completed on July 31, 2025. Frankenius Equity AB accepted the Exchange and was issued 759,000 shares of Common Stock in exchange for their 230,000 shares of Preferred Stock.Item 4 of the SCHEDULE 13D/A filed 2025-08-04

Timeline

Swipe the table sideways to see every column.

Questions about who owns TriSalus Life Sciences, Inc.

Who owns TriSalus Life Sciences, Inc.?

On this page, 5 holders' latest ownership filings report 5% or more of TriSalus Life Sciences, Inc.: Frankenius Equity AB (14%, Schedule 13D/A, filed 2025-08-04), First Light Asset Management, LLC (10.74%, Schedule 13G/A, filed 2026-07-07), Mats Wahlstrom (6%, Schedule 13D/A, filed 2025-08-01), Utmost Group PLC (5.71%, Schedule 13G, filed 2026-05-12) and James J. Pallotta (5.2%, Schedule 13G/A, filed 2026-05-20).

Who are the largest shareholders of TriSalus Life Sciences, Inc.?

By the share each holder's latest filing reports, the largest holders of TriSalus Life Sciences, Inc. on this page are Frankenius Equity AB (14%), First Light Asset Management, LLC (10.74%) and Mats Wahlstrom (6%).

When did Frankenius Equity AB buy into TriSalus Life Sciences, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Frankenius Equity AB on this page is the Schedule 13D/A, filed 2025-08-04, reporting 14%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for TriSalus Life Sciences, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for TriSalus Life Sciences, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when TriSalus Life Sciences, Inc. is mentioned again
• Find former TriSalus Life Sciences, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes